Evidence map›Paper›PMID 32466298›Full record

ArticleMolecules (Basel, Switzerland)2020

Dual miRNases for Triple Incision of miRNA Target: Design Concept and Catalytic Performance.

Olga Patutina, Daria Chiglintseva, Elena Bichenkova, Svetlana Gaponova, Nadezhda Mironova, Valentin Vlassov, Marina Zenkova

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Olga PatutinaLaboratory of Nucleic Acids Biochemistry, Institute of Chemical Biology and Fundamental Medicine SB RAS, Lavrentiev's ave. 8, 630090 Novosibirsk, Russia.
Daria ChiglintsevaLaboratory of Nucleic Acids Biochemistry, Institute of Chemical Biology and Fundamental Medicine SB RAS, Lavrentiev's ave. 8, 630090 Novosibirsk, Russia.
Elena BichenkovaSchool of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Oxford Rd, Manchester, M13 9PT, UK.
Svetlana GaponovaLaboratory of Nucleic Acids Biochemistry, Institute of Chemical Biology and Fundamental Medicine SB RAS, Lavrentiev's ave. 8, 630090 Novosibirsk, Russia.
Nadezhda MironovaLaboratory of Nucleic Acids Biochemistry, Institute of Chemical Biology and Fundamental Medicine SB RAS, Lavrentiev's ave. 8, 630090 Novosibirsk, Russia.
Valentin VlassovLaboratory of Nucleic Acids Biochemistry, Institute of Chemical Biology and Fundamental Medicine SB RAS, Lavrentiev's ave. 8, 630090 Novosibirsk, Russia.
Marina ZenkovaLaboratory of Nucleic Acids Biochemistry, Institute of Chemical Biology and Fundamental Medicine SB RAS, Lavrentiev's ave. 8, 630090 Novosibirsk, Russia.
Institute of Chemical Biology and Fundamental Medicine · RUSiberian Branch of the Russian Academy of Sciences · RUUniversity of Manchester · GB

Funding

BBSRC BB/K012622/1EPSRC EP/G03737X/1EPSRC EPSRC EP/E003400/1Russian Science Foundation 19-14-00250Russian State funded budget project AAAA-A17-117020210024-8
6 · The paper itself

Abstract

Irreversible destruction of disease-associated regulatory RNA sequences offers exciting opportunities for safe and powerful therapeutic interventions against human pathophysiology. In 2017, for the first time we introduced miRNAses-miRNA-targeted conjugates of a catalytic peptide and oligonucleotide capable of cleaving an miRNA target. Herein, we report the development of Dual miRNases against oncogenic miR-21, miR-155, miR-17 and miR-18a, each containing the catalytic peptide placed in-between two short miRNA-targeted oligodeoxyribonucleotide recognition motifs. Substitution of adenines with 2-aminoadenines in the sequence of oligonucleotide "shoulders" of the Dual miRNase significantly enhanced the efficiency of hybridization with the miRNA target. It was shown that sequence-specific cleavage of the target by miRNase proceeded metal-independently at pH optimum 5.5-7.5 with an efficiency varying from 15% to 85%, depending on the miRNA sequence. A distinct advantage of the engineered nucleases is their ability to additionally recruit RNase H and cut miRNA at three different locations. Such cleavage proceeds at the central part by Dual miRNase, and at the 5'- and 3'-regions by RNase H, which significantly increases the efficiency of miRNA degradation. Due to increased activity at lowered pH Dual miRNases could provide an additional advantage in acidic tumor conditions and may be considered as efficient tumor-selective RNA-targeted therapeutic.

Indexed as

2-AminopurineBase SequenceBiocatalysisCatalytic DomainHumansHydrogen-Ion ConcentrationMicroRNAsOligonucleotidesPeptidesRibonucleasesRNA Stability2,6-diaminopurine2-AminopurineMicroRNAsMIRN155 microRNA, humanMIRN17 microRNA, humanMIRN18A microRNA, humanMIRN21 microRNA, humanOligonucleotidesPeptidesRibonucleasesanti-miRNA therapyartificial ribonucleasemiRNaseoligonucleotide-peptide conjugateoncogenic miRNARNA cleavageRNase H

Identifiers

PMID32466298
PMCPMC7287882
OpenAlexW3027755698

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.